FACTBOX-World's top-selling drugs in 2014 vs 2010
April 13 (Reuters) - Roche's (ROG.VX) cancer drug Avastin is expected to be the world's biggest-selling drug in 2014, as today's two top blockbusters -- Lipitor and Plavix -- lose patent protection in 2011 and 2012.
In four years' time, the prescription drug league table will look very different, reflecting the growing commercial dominance of injectable biotech drugs, especially for cancer and rheumatoid arthritis.
Consensus sales forecasts for world's top 10 drugs in 2014: 1. Avastin (cancer) Roche $8.9 bln 2. Humira (arthritis) Abbott (ABT.N) $8.5 bln 3. Enbrel (arthritis) Pfizer(PFE.N)/Amgen(AMGN.O) $8.0 bln 4. Crestor (cholesterol) AstraZeneca (AZN.L) $7.7 bln 5. Remicade (arthritis) Merck(MRK.N)/J&J(JNJ.N) $7.6 bln 6. Rituxan (cancer) Roche $7.4 bln 7. Lantus (diabetes) Sanofi-Aventis (SASY.PA) $7.1 bln 8. Advair (asthma/COPD) GlaxoSmithKline (GSK.L) $6.8 bln 9. Herceptin (cancer) Roche $6.4 bln 10.NovoLog (diabetes) Novo Nordisk (NOVOb.CO) $5.7 bln
Consensus forecasts for 2010: 1. Lipitor (cholesterol) Pfizer $11.7 bln 2. Plavix (anticlotting) Sanofi/Bristol (BMY.N) $9.6 bln 3. Advair (asthma/COPD) GlaxoSmithKline $9.0 bln 4. Remicade (arthritis) Merck/J&J $7.4 bln 5. Enbrel (arthritis) Pfizer/Amgen $7.1 bln 6. Humira (arthritis) Abbott $6.8 bln 7. Avastin (cancer) Roche $6.7 bln 8. Rituxan (cancer) Roche $6.1 bln 9. Diovan (hypertension) Novartis $6.0 bln 10.Crestor (cholesterol) AstraZeneca $5.8 bln
Source: Thomson Reuters
(Reporting by Ben Hirschler, Editing by Sitaraman Shankar)
- Ukraine accuses Russia of "undisguised aggression" as rebels advance |
- Disruptive Hong Kong protests loom after China rules out democracy |
- Syrian army, rebels fight on Golan where peacekeepers held |
- European investors look past Ukraine, focus on ECB
- NATO to create new 'spearhead' force to respond to crises